Trials Sponsors Conditions Drugs Pricing

Conditions

Familial Combined Hyperlipidemia Familial Hypertriglyceridemia Metabolic Syndrome

Outcome Measures

Primary Outcomes (1)

plasma triglyceride concentrations
3 months

Secondary Outcomes (2)

hepatic insulin sensitivity
3 months
heptic triglyceride content
3 months

Study Arms (2)

A

ACTIVE COMPARATOR

chenodeoxycholic acid treatment

Drug: chenodeoxycholic acid

B

PLACEBO COMPARATOR

placebo treatment

Drug: placebo capsules

Interventions

chenodeoxycholic acidDrug

chenodeoxycholic acid 500 mg capsules tid po

placebo capsulesDrug

placebo capsules containing mannitol tid po

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age between 18 and 65 years.
Patients with a metabolic syndrome defined by the presence of \>= 3 of the following criteria:

Sponsors & Collaborators

University Hospital, Basel, Switzerland
Otherlead

Study Sites (1)

University Hospital Basel

Basel, Basel, 4031, Switzerland

MeSH Terms

Conditions

Metabolic SyndromeHyperlipoproteinemia Type IVHyperlipidemia, Familial Combined

Interventions

Chenodeoxycholic Acid

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesLipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

Stefan Bilz, MD
Cantonal Hospital of St. Gallen
PRINCIPAL INVESTIGATOR

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: early phase 1
Allocation: NON RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 24, 2007

First Posted

April 25, 2007

Study Start

October 2004

Date type not reported

This date has not been verified as actual or estimated.

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

A

B

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

A

B

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations